Hikma Pharmaceuticals USA, Inc.: Remifentanil Hydrochloride Injection shortage update (unavailable from this maker)
Hikma Pharmaceuticals USA, Inc.: Remifentanil Hydrochloride Injection shortage update (unavailable from this maker). Its amount of 3 is above the median of 3 (62nd percentile). Dated 22 days ago, it is in the active follow-up window. Score 70/100. As of 2026-11-04, from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list).
Data as of · Compiled by Zalwin from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
amount: 3 · 62th percentile of 353 DrugShortagePulse records · 1.0x the median
Free preview: all 13 published fields of this record are shown below. Locked: 352 related DrugShortagePulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Manufacturer | Hikma Pharmaceuticals USA, Inc. |
| Drug | Remifentanil Hydrochloride Injection |
| Dosage form | Injection |
| Therapeutic category | Analgesia/Addiction |
| Status | Current |
| Stage | Shortage revised (availability or dates changed) |
| Availability | Unavailable |
| Reason | Demand increase for the drug |
| Presentations affected | 3 |
| Package NDCs | 0143-9392-10, 0143-9393-10, 0143-9391-10 |
| Manufacturer supply note | Estimated recovery: TBD |
| First posted | 2022-06-28 |
| Updated | 2026-10-14 |
| amount percentile | 62th of 353 (median 3, 1.0x median) |
| Peer records CSV (353 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Hikma Pharmaceuticals USA, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Hikma Pharmaceuticals USA + all 353 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Manufacturer · Drug · Stage · Availability · Updated · official source URL
- Source agency: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
- Record date: 2026-10-14
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top DrugShortagePulse records: Sanofi-Aventis U.S. LLC · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Browse all by state and category →
LIVE PUBLIC DATA Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) · Last refreshed: Wed, 04 Nov 2026 06:10:12 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
70 / 100 Score
- Shortage details just changed.
- Unavailable from this manufacturer.
- Sterile injectable: hospital and 503B demand.
What is the DrugShortagePulse record for Hikma Pharmaceuticals USA, Inc.?
Hikma Pharmaceuticals USA, Inc.'s Remifentanil Hydrochloride Injection is on the FDA drug shortage list. Shortage revised (availability or dates changed); unavailable from this maker. Last updated 2026-10-14.
How does Hikma Pharmaceuticals USA, Inc. compare to other DrugShortagePulse records?
Its amount of 3 sits in the upper half (62th percentile) of 353 records; the median is 3. It is 22 days old, still within a typical 45-day follow-up window. Its Score of 70/100 puts it among the stronger signals in this feed.
Hikma Pharmaceuticals USA, Inc. vs. top 3 peers
| Organization | Amount | Percentile | Record date |
|---|---|---|---|
| Hikma Pharmaceuticals USA, Inc. | 3 | 62nd | 2026-10-14 |
| Pfizer Inc. | 3 | 62nd | 2026-10-21 |
| Hospira, Inc., a Pfizer Company | 3 | 62nd | 2026-10-21 |
| Pfizer Inc. | 3 | 62nd | 2026-10-21 |
Related records
DrugShortagePulse: Shortage revised (availability or dates changed) DrugShortagePulse: Analgesia/Addiction
How to monitor Hikma Pharmaceuticals USA, Inc. and peer analgesia/addiction records
Get new DrugShortagePulse records like Hikma Pharmaceuticals USA, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new shortages in your categories
DrugShortagePulse emails new and changed FDA drug shortages matching your therapeutic categories.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.